Oncolytic adenoviruses represent a novel class of anticancer agents. Their efficacy in killing cancer cells is variable, suggesting that there is room for improvement. Host miRNAs have been shown to play important roles in susceptibility of cells to replication of different viruses. This study investigated if adenovirus replication in human prostate cancer cells is influenced by host cell miRNA expression. To this end, human miRNA expression in response to adenovirus infection was analyzed, and functional screens for lytic adenovirus replication were performed using synthetic miRNA mimic and inhibitor libraries. Adenovirus infection generally reduced miRNA expression. On top of this nonspecific interference with miRNA biogenesis, a set of miRNAs, including in particular miR-222, was found specifically reduced. Another set of miRNAs was found to promote adenovirus-induced death of prostate cancer cells. In most cases, this did not stimulate adenovirus propagation. The exception was miR-26b. Overexpression of miR-26b inhibited adenovirus-induced NF-κB activation, augmented adenovirus-mediated cell death, increased adenovirus progeny release, and promoted adenovirus propagation and spread in several human prostate cancer cell lines. This suggests that miR-26b is particularly useful to be combined with oncolytic adenovirus for more effective treatment of prostate cancer.
Get full access to this article
View all access options for this article.
References
1.
AlemanyR. Cancer selective adenoviruses. Mol Aspects Med, 2007; 28:42–58.
2.
PesonenS, KangasniemiL, HemminkiA. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm, 2011; 8:12–28.
3.
BraithwaiteAW, RussellIA. Induction of cell death by adenoviruses. Apoptosis, 2001; 6:359–370.
4.
ChaurushiyaMS, WeitzmanMD. Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair (Amst), 2009; 8:1166–1176.
5.
van BeusechemVW, van den DoelPB, GrillJ, et al.Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res, 2002; 62:6165–6171.
6.
HallAR, DixBR, O'CarrollSJ, et al.p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med, 1998; 4:1068–1072.
7.
SauthoffH, PipiyaT, HeitnerS, et al.Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther, 2002; 13:1859–1871.
8.
GraatHC, CaretteJE, SchagenFH, et al.Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther, 2007; 6:1552–1561.
9.
HeidemanDA, SteenbergenRD, van der TorreJ, et al.Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol Ther, 2005; 12:1083–1090.
10.
van BeusechemVW, van den DoelPB, GerritsenWR. Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. Mol Cancer Ther, 2005; 4:1013–1018.
11.
MahajanVS, DrakeA, and ChenJ. Virus-specific host miRNAs: antiviral defenses or promoters of persistent infection?. Trends Immunol, 2009; 30:1–7.
12.
ScariaV, HariharanM, PillaiB, et al.Host–virus genome interactions: macro roles for microRNAs. Cell Microbiol, 2007; 9:2784–2794.
13.
DingSW, VoinnetO. Antiviral immunity directed by small RNAs. Cell, 2007; 130:413–426.
14.
BackesS, LangloisRA, SchmidS, et al.The mammalian response to virus infection is independent of small RNA silencing. Cell Rep, 2014; 8:114–125.
15.
HuangJ, WangF, ArgyrisE, et al.Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med, 2007; 13:1241–1247.
16.
LecellierCH, DunoyerP, ArarK, et al.A cellular microRNA mediates antiviral defense in human cells. Science, 2005; 308:557–560.
17.
OtsukaM, JingQ, GeorgelP, et al.Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity, 2007; 27:123–134.
18.
SongL, LiuH, GaoS, et al.Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol, 2010; 84:8849–8860.
19.
GuptaA, GartnerJJ, SethupathyP, et al.Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nature, 2006; 442:82–85.
20.
SullivanCS, GrundhoffAT, TevethiaS, et al.SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature, 2005; 435:682–686.
21.
JoplingCL, YiM, LancasterAM, et al.Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005; 309:1577–1581.
LandgrafP, RusuM, SheridanR, et al.A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 2007; 129:1401–1414.
24.
LuJ, GetzG, MiskaEA, et al.MicroRNA expression profiles classify human cancers. Nature, 2005; 435:834–838.
25.
RosenfeldN, AharonovR, MeiriE, et al.MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol, 2008; 26:462–469.
26.
VoorhoevePM, le SageC, SchrierM, et al.A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell, 2006; 124:1169–1181.
27.
GrillJ, LamfersML, van BeusechemVW, et al.The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther, 2002; 6:609–614.
28.
IdemaS, DirvenCM, van BeusechemVW, et al.Objective determination of the oncolytic potency of conditionally-replicating adenoviruses using mathematical modeling. J Gene Med, 2010; 12:564–571.
29.
HeTC, ZhouS, da CostaLT, et al.A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A, 1998; 95:2509–2514.
30.
CaretteJE, GraatHC, SchagenFH, et al.Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med, 2005; 7:1053–1062.
31.
FueyoJ, Gomez-ManzanoC, AlemanyR, et al.A mutant oncolytic adenovirus targeting the Rb pathway produces anti- glioma effect in vivo. Oncogene, 2000; 19:2–12.
KalAJ, van ZonneveldAJ, BenesV, et al.Dynamics of gene expression revealed by comparison of serial analysis of gene expression transcript profiles from yeast grown on two different carbon sources. Mol Biol Cell, 1999; 10:1859–1872.
37.
ChenC, RidzonDA, BroomerAJ, et al.Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 2005; 33:e179.
38.
ChenCY, ChangJT, HoYF, et al.MiR-26 down-regulates TNF-alpha/NF-kappaB signalling and IL-6 expression by silencing HMGA1 and MALT1. Nucleic Acids Res, 2016; 44:3772–3787.
39.
ZhaoN, WangR, ZhouL, et al.MicroRNA-26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer, 2014; 13:35.
40.
PalmerDH, ChenMJ, SearlePF, et al.Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Ther, 2005; 12:1187–1197.
41.
AnderssonMG, HaasnootPC, XuN, et al.Suppression of RNA interference by adenovirus virus-associated RNA. J Virol, 2005; 79:9556–9565.
42.
LuS, CullenBR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol, 2004; 78:12868–12876.
43.
CaretteJE, OvermeerRM, SchagenFH, et al.Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res, 2004; 64:2663–2667.
44.
YooJY, KimJH, KwonYG, et al.VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther, 2007; 15:295–302.
45.
ZhangYA, NemunaitisJ, SamuelSK, et al.Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res, 2006; 66:9736–9743.
46.
BandopadhyayM, BanerjeeA, SarkarN, et al.Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes. BMC Cancer, 2014; 14:721.
47.
ImigJ, MotschN, ZhuJY, et al.microRNA profiling in Epstein–Barr virus–associated B-cell lymphoma. Nucleic Acids Res, 2011; 39:1880–1893.
48.
WaldAI, HoskinsEE, WellsSI, et al.Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck, 2011; 33:504–512.
49.
WangFZ, WeberF, CroceC, et al.Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J Virol, 2008; 82:9065–9074.
50.
WuYH, HuTF, ChenYC, et al.The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility. Blood, 2011; 118:2896–2905.
51.
BuckAH, PerotJ, ChisholmMA, et al.Post-transcriptional regulation of miR-27 in murine cytomegalovirus infection. RNA, 2010; 16:307–315.
52.
LagosD, PollaraG, HendersonS, et al.miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol, 2010; 12:513–519.
53.
HottigerMO, NabelGJ. Viral replication and the coactivators p300 and CBP. Trends Microbiol, 2000; 8:560–565.
54.
TeodoroJG, BrantonPE. Regulation of apoptosis by viral gene products. J Virol, 1997; 71:1739–1746.
55.
GaoJ, LiuQG. The role of miR-26 in tumors and normal tissues (Review). Oncol Lett, 2011; 2:1019–1023.
56.
KohCM, IwataT, ZhengQ, et al.Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget, 2011; 2:669–683.
57.
KotaJ, ChivukulaRR, O'DonnellKA, et al.Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009; 137:1005–1017.
58.
ZhuY, LuY, ZhangQ, et al.MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res, 2012; 40:4615–4625.
59.
HeiseC, HermistonT, JohnsonL, et al.An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med, 2000; 6:1134–1139.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
